Olympus earns top recognition for climate action

JAPAN – Olympus Corporation, a global MedTech company dedicated to improving health and safety, has been recognized as an “A List” company by CDP, a leading environmental non-profit organization.

This prestigious rating acknowledges companies that excel in setting and achieving climate-related goals.

CDP evaluates businesses worldwide based on their efforts in climate action, water resource management, and environmental sustainability.

This year, nearly 24,800 companies participated in the assessment, including over 2,100 from Japan. Olympus stood out for its strong environmental initiatives, earning it a place among the top-rated organizations.

As part of its Environmental, Social, and Governance (ESG) strategy, Olympus has made carbon neutrality and a circular economy key priorities.

To support a decarbonized future, the company set a goal in May 2023 to achieve net-zero greenhouse gas emissions across its supply chain by 2040.

In November 2023, Olympus received a net-zero certification from the Science Based Targets initiative (SBTi), reinforcing its dedication to reducing its carbon footprint.

Reducing environmental impact

Olympus is actively working to lower greenhouse gas emissions by improving manufacturing processes, increasing energy efficiency, and transitioning to renewable energy sources.

The company also recognizes the need to reduce emissions across its entire supply chain. To achieve this, Olympus is developing eco-friendly products, optimizing logistics, and collaborating with suppliers to set clear emission reduction targets.

Highlighting the company’s dedication to sustainability, Yasuo Takeuchi, Olympus Director and Executive Chairman, stated:

“At Olympus, ESG principles are embedded in our corporate strategy as we work toward making people’s lives healthier, safer, and more fulfilling. Our recognition on CDP’s A List reflects our commitment to climate action and transparent environmental disclosure. We believe that contributing to the sustainable development of society will enable Olympus to achieve long-term growth and value creation.”

Pharmaceutical industry’s role in climate action

Olympus is not alone in its efforts. The pharmaceutical industry is increasingly prioritizing sustainability by reducing its environmental footprint.

Companies like GlaxoSmithKline (GSK) and AstraZeneca are developing low-carbon asthma inhalers to minimize greenhouse gas emissions. GSK’s revised Ventolin inhaler could cut its carbon output by over 40%, while AstraZeneca’s improved Breztri inhaler is expected to lower emissions by nearly 20%.

Beyond individual company efforts, industry-wide initiatives are driving sustainability. In 2021, major pharmaceutical companies introduced Energize, a global program designed to help suppliers transition to renewable energy.

Additionally, the UNFCCC’s Climate Champions have set a goal for 95% of pharmaceutical and MedTech laboratories to achieve the highest My Green Lab certification by 2030.

This certification focuses on energy efficiency, waste reduction, and sustainable resource use.